Business Wire

Knopp Biosciences to Present Data Characterizing Its Potassium Channel Activator Candidate for the Treatment of KCNQ2 Epileptic Encephalopathy at the American Epilepsy Society’s 2019 Annual Meeting

Share

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases with high unmet need, today announced that data from its Kv7 platform will be presented at the American Epilepsy Society’s (AES) 2019 Annual Meeting from December 6-10 in Baltimore.

“We look forward to sharing progress on our lead drug candidate for the treatment of KCNQ2 epileptic encephalopathy as we advance the understanding of ion channel activators and the important role they play in epilepsy and other neurological conditions with high unmet need,” said Michael Bozik, M.D., Chief Executive Officer of Knopp Biosciences.

Ion channels are proteins that regulate the excitability of cells, and drugs that modulate ion channels play an important role in treating a variety of neurological and smooth muscle conditions. Among ion channel targets, potassium channels play a key role in the pathophysiology of epilepsy and other unmet needs in diseases of the nervous system. Knopp is advancing a library of Kv7.2/7.3 channel activators to modulate this key ion channel in nerve cells, targeting a devastating genetic mutation associated with neonatal encephalopathy, as well as other rare epilepsies and neuropathic pain.

Details related to Knopp Biosciences’ AES abstracts and poster presentations can be found in the table below.

Follow Knopp Biosciences on Twitter via @KnoppBio and keep up to date with AES Annual Meeting news and updates using the hashtag #AES2019.

Abstract Title

Abstract Number / Presentation Details

Discovery and Characterization of KB-3061: A Potent Kv7.2/7.3 Ion Channel Activator for the Treatment of KCNQ2-Neonatal Epileptic Encephalopathy

Abstract 3.045: Poster Presentation
Presenter: Kelly E. Picchione, Ph.D., Knopp Biosciences
Date: December 9
Time: 12:00 - 1:45 PM EST
Location: Hall E, Level 100

KB-3061 is a Potent Activator of Wild Type KCNQ Channels and Restores Current to KCNQ2 Encephalopathy Variants In Vitro

 

Abstract 3.047: Poster Presentation
Presenter: Zhigang Ji, Ph.D., Baylor College of Medicine
Date: December 9
Time: 12:00 - 1:45 PM EST
Location: Hall E, Level 100

ABOUT KNOPP BIOSCIENCES LLC
Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases of high unmet need. Knopp’s clinical-stage small molecule, dexpramipexole, is in Phase 2 clinical trials for severe eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small molecule treatments for neonatal epileptic encephalopathy, other rare epilepsies, and neuropathic pain. Please visit www.knoppbio.com.

Knopp's Kv7 research is supported under Award Number U44NS093160 and Award Number U44NS115732 of the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH). The content of this announcement is solely the responsibility of Knopp and does not necessarily represent the views of the NIH.

This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.

Contact information

Media inquiries:
Kate Coyle
kate.coyle@icrinc.com
203-682-8210

Surabhi Verma
surabhi.verma@icrinc.com
646-677-1825

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HCL Technologies Honors Global Goodwill Champions at the 2020 World Economic Forum in Davos24.1.2020 12:47:00 EETPress release

HCL Technologies (HCL), a leading global technology company, today presented its Wave Maker Awards 2020, commemorating global goodwill champions from around the world. The award ceremony, which was held at the HCL Pavilion in Davos, celebrated organizations and individuals passionately committed to such noble causes as diversity & inclusion, education & community upliftment, environment & sustainability, and technology for change. Special guest at the awards was Australian cricket legend Glenn McGrath, who is also founder of the McGrath Foundation, which provides support for Australian women diagnosed with breast cancer and their families. The award recipients were; Lois Auta, Founder and Executive Director of Cedar Seed Foundation, which supports persons with disabilities to participate in all aspects of life; Chido Govera, Founder and Director of The Future of Hope Foundation (TFoHF), which supports marginal and vulnerable members of society through entrepreneurial and self-developme

Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria24.1.2020 09:00:00 EETPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the decision to pause dosing patients in the global Phase III (PVO-1A-301) study designed to evaluate the efficacy and safety of palovarotene in patients with fibrodysplasia ossificans progressiva (FOP), as well as the ongoing Phase II (PVO-1A-202/204) extension studies. In both the Phase III and Phase II extension studies, palovarotene is dosed both chronically (daily) and episodically (during flare-ups). The decision to pause dosing patients in the trial is based on results of a futility analysis reviewed by the Independent Data Monitoring Committee (IDMC) as part of the prespecified interim analysis. The results of a futility analysis indicated that the Phase III FOP trial was unlikely to meet its primary efficacy endpoint (annualized change in new HO volume as compared with Natural History Studyi) upon completion. Despite the results of the prespecified interim analysis, signals of encouraging therapeutic activity w

Amazentis Announces the Launch of Timeline™ Cellular Nutrition at the World Economic Forum in Davos23.1.2020 23:56:00 EETPress release

Amazentis announces the debut of Timeline, a next generation nutrition product designed to promote healthy aging, as part of the Swiss Food & Nutrition Valley in the House of Switzerland at the World Economic Forum in Davos, Switzerland. Given the increase in the aging population globally -- according to a 2019 Deutsche Bank study, there are more people on Earth older than sixty five than younger than five for the first time -- it is imperative for consumers to take proactive measures to maintain a high quality of life, for as long as they live. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200123005820/en/ (Photo: Business Wire) Timeline contains the proprietary nutrient Mitopure™, a highly pure form of Urolithin A. After a decade of rigorous research by leading scientists around the world, Mitopure has been shown to help counter age-associated cellular and muscular decline by revitalizing the mitochondria, the powerplants

Lionbridge Names Corinne Saunders as Managing Director, EMEA23.1.2020 21:00:00 EETPress release

Today, Lionbridge, a global leader in localization and data training services, announced that former Wolters Kluwer executive Corinne Saunders has joined the company as managing director of EMEA. Lionbridge currently has 51 offices in 26 countries around the world; Saunders will oversee EMEA sales, account management, and marketing operations. “Europe represents a large portion of our overall business and will continue to be a growth area for our AI and localization businesses. I am very happy that Corinne is coming onboard to lead our efforts across EMEA,” says Lionbridge Chief Executive Officer John Fennelly. “Throughout her career, she’s shown an exceptional ability for driving innovation and understanding customer needs.” While at Wolters Kluwer, Saunders served as chief executive officer for emerging and developing markets. Saunders will work from Brussels, Belgium. About Lionbridge Lionbridge partners with brands to break barriers and build bridges all over the world. For more th

President Bill Clinton to Keynote 2020 World Patient Safety, Science & Technology Summit23.1.2020 20:34:00 EETPress release

President Bill Clinton, the 42nd President of the United States, will be the closing keynote speaker at the Patient Safety Movement Foundation’s 2020 World Patient Safety, Science & Technology Summit. The 8th annual Summit will be held in Huntington Beach, California, beginning with a Pre-Summit Symposium on Thursday, March 5th. At the 2020 Summit, hospital leaders, medical and information technology innovators, patient advocates, policy makers and government officials collaborate and discuss best practices solutions to eliminate preventable patient deaths in hospitals around the world. The event is co-convened with the International Society for Quality in Health Care (ISQua), the American Society of Anesthesiologists and the European Society of Anaesthesiology. The 2020 Summit is scheduled for March 5 – 7th, 2020, at the Waterfront Beach Resort in Huntington Beach, California. For more information about the 2020 World Patient Safety, Science & Technology Summit, visit http://patientsa

Covantis initiative announces technology partner - ConsenSys23.1.2020 18:00:00 EETPress release

The founding members of the Covantis initiative, which aims to modernize global trade operations, have announced the selection of ConsenSys, a market-leading Ethereum blockchain technology company, as the lead technology partner to develop its transformative platform. “The founders set up a robust selection process, including a two week hackathon, to ensure that we chose the right technology partner to meet our industry’s needs,” said Stefano Rettore, independent advisor to the project. “ConsenSys presented prototypes that demonstrated excellence in its field and has a track record of using blockchain technology to digitize processes in the commodity trade finance industry. We are confident this partnership will allow us to build a first-class product, centered around unparalleled functionality, security and privacy.” ConsenSys will leverage its enterprise-ready blockchain solutions and services, including PegaSys Orchestrate, Kaleido and MythX to build the blockchain network on Ethere

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom